P114 Safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Phase 2 results from a phase 1/2 study

✍ Scribed by Petrylak, D.; Gandhi, J.; Clark, W.R.; Heath, E.I.; Lin, J.; Oh, W.K.; Agus, D.B.; Carthon, B.; Moran, S.; Mortimer, P.; Liu, G.

• Book ID: 122720202
• Publisher: Elsevier Science
• Year: 2012
• Tongue: English
• Weight: 61 KB
• Volume: 11
• Category: Article
• ISSN: 1569-9056
• DOI: 10.1016/S1569-9056(13)60480-7